Can Statins Prevent Dementia? What the Evidence Shows

Originally published March 2026 · Updated May 2026 with the February 2026 Alzheimer's & Dementia UK Biobank causal machine learning study, the 2025 Frontiers in Pharmacology systematic review and meta-analysis of cohort studies, and the BHF April 2025 LDL and dementia risk analysis

More than 5.3 million people in England are prescribed statins — one of the most widely used medications in the world. They take them to lower LDL cholesterol and reduce the risk of heart attack and stroke. But a growing body of research is asking a different question: could statins also protect the brain?

The question is not new. Studies suggesting a possible link between statin use and lower dementia risk have been appearing for over two decades. What is new is the sophistication of the methods being applied to answer it — and a February 2026 study using UK Biobank data and causal machine learning that provides the most nuanced picture yet of who might benefit, and who might not.

The honest answer is: probably yes, for some people, through mechanisms that go beyond cholesterol. But not for everyone. And not enough on its own to meaningfully change dementia risk without the lifestyle foundations that matter more.

TL;DR

• A 2025 BHF analysis of a large cohort study found that statin users with healthy LDL cholesterol levels were 13% less likely to develop dementia and 12% less likely to develop Alzheimer's related dementia compared to non-users with the same LDL levels — suggesting a benefit beyond cholesterol reduction alone.
• A February 2026 UK Biobank study published in Alzheimer's & Dementia used causal machine learning across 18,366 participants to identify subgroups where statins produce the greatest dementia risk reduction — finding that people with higher genetic risk for Alzheimer's disease benefit most.
• A 2025 systematic review and meta-analysis published in Frontiers in Pharmacology confirmed a protective association between statin use and reduced dementia and Alzheimer's disease incidence across cohort studies.
• The evidence is observational and the overall effect size is modest — statins are not a dementia prevention drug and should not be started for this purpose alone.
• The mechanisms through which statins might protect the brain go beyond cholesterol — they include anti-inflammatory effects, reduction of amyloid precursor processing, and improved cerebrovascular function.
• More than 900,000 people in the UK live with dementia. If statins provide even modest protection in high-risk groups already taking them for cardiovascular reasons, the public health implications are significant.

The Cholesterol-Dementia Connection

Before examining what statins specifically do, it helps to understand why cholesterol is relevant to dementia at all.

LDL cholesterol — often called "bad" cholesterol — can clog up blood vessels and increase the risk of stroke, heart disease and dementia. The vascular pathway is the most established connection: high LDL promotes atherosclerosis, which reduces cerebral blood flow, which accelerates cognitive decline through vascular dementia mechanisms and compounds Alzheimer's disease pathology.

But cholesterol also has a more direct role in Alzheimer's disease biology. Cholesterol metabolism in the brain influences the processing of amyloid precursor protein — the protein that, when misprocessed, produces the amyloid-beta fragments that aggregate into the plaques characteristic of Alzheimer's disease. Statins not only lower serum cholesterol levels but also inhibit pivotal enzymatic reactions that lead to amyloid deposition and plaque formation — both considered cornerstone pathways in Alzheimer's disease development.

This dual pathway — vascular protection and direct amyloid processing effects — is why statins have attracted sustained research interest for dementia prevention beyond their established cardiovascular benefits.

The 2025 BHF Analysis: 13% Lower Dementia Risk

The British Heart Foundation published an accessible analysis in April 2025 of a large cohort study examining statin use and dementia risk. The findings produced significant UK media coverage — and they are worth understanding precisely.

Researchers found that those with healthy LDL cholesterol levels who took statins were 13% less likely to have dementia and 12% less likely to have Alzheimer's related dementia, compared to those with the same LDL levels who did not take them.

The "same LDL levels" comparison is the most important element of this finding. It suggests that statins are producing a dementia risk reduction that is not simply explained by their effect on LDL — because both groups had similar LDL. This points toward the pleiotropic effects of statins — their anti-inflammatory, antioxidant, and vascular effects that operate independently of cholesterol lowering.

The BHF noted that while these findings are exciting, the evidence is not yet conclusive. Statins alone would never guarantee protection against dementia because there are many more risk factors for developing dementia than high cholesterol — including high blood pressure, atrial fibrillation, smoking, drinking alcohol, and having an unhealthy diet.

This framing is the correct one. A 13% risk reduction is meaningful at population level. It is not transformative at individual level — particularly when lifestyle factors that individually produce larger risk reductions (exercise, sleep, diet) are not optimised.

The February 2026 UK Biobank Study: Who Benefits Most

The most methodologically sophisticated recent contribution to this question is a February 2026 study published in Alzheimer's & Dementia, using UK Biobank data and causal machine learning to assess heterogeneous treatment effects of statins on dementia.

Among 18,366 participants, the overall adjusted risk difference for all-cause dementia was −1.0‰ — a small overall effect that was not statistically significant across the whole population. However, the causal machine learning analysis identified subgroups with meaningfully different treatment effects.

The key finding: researchers identified subgroups by polygenic risk score for Alzheimer's disease excluding APOE genotype — the "non-APOE PRS" — as the primary modifier of statin treatment effects on dementia risk.

In plain terms: people with higher genetic risk for Alzheimer's disease — as measured by genetic variants other than the well-known APOE4 gene — showed the greatest dementia risk reduction from statin use. People without elevated genetic risk showed little or no benefit.

This finding is important for two reasons. First, it explains why previous studies have produced inconsistent results — if statins primarily benefit people with specific genetic risk profiles, studies that do not account for this heterogeneity will find average effects that underestimate the benefit in high-risk groups and overestimate it in low-risk ones. Second, it points toward a future in which genetic risk stratification could identify which statin users are most likely to receive brain health benefits alongside their cardiovascular benefits.

The 2025 Systematic Review: The Full Evidence Picture

The February 2025 systematic review and meta-analysis published in Frontiers in Pharmacology provides the broadest synthesis of the cohort study evidence available.

Prior meta-analyses have identified the protective effects of statins in reducing the development of dementia. The 2025 review incorporated a larger dataset, allowing for a broader examination of outcomes and providing a more robust and nuanced understanding of the relationship between statin use and dementia risk.

The review confirmed a statistically significant association between statin use and reduced dementia risk across cohort studies — with the protective association more consistent for Alzheimer's disease than for vascular dementia specifically. This is counterintuitive given that statins' primary mechanism is vascular — but may reflect the amyloid processing effects that operate through a different pathway.

The review also confirmed the consistency of the pleiotropic effects hypothesis — that statins' brain benefits operate through anti-inflammatory and antioxidant mechanisms independent of cholesterol reduction. In addition to the primary cholesterol-lowering mechanism, other mechanisms have been investigated due to the pleiotropic effects independent of cholesterol observed with statins.

How Statins Might Protect the Brain

The mechanisms through which statins might reduce dementia risk — beyond cholesterol — are increasingly well characterised.

Anti-inflammatory effects — chronic neuroinflammation is a consistent feature of Alzheimer's disease pathology. Statins have anti-inflammatory properties that reduce microglial activation and pro-inflammatory cytokine production in the brain — effects that are independent of cholesterol and may directly attenuate neuroinflammatory progression.

Improved cerebrovascular function — statins improve endothelial function and reduce arterial stiffness, improving cerebral blood flow. Adequate cerebral perfusion is essential for amyloid clearance through the glymphatic system — the brain's waste clearance mechanism that operates primarily during deep sleep. Impaired cerebral perfusion impairs amyloid clearance and accelerates Alzheimer's pathology.

Amyloid precursor processing — statins inhibit enzymatic pathways involved in amyloid precursor protein processing, potentially reducing the production of amyloid-beta fragments that aggregate into plaques. This direct effect on Alzheimer's disease pathological processes may be the mechanism through which statin use is associated with reduced Alzheimer's risk independently of vascular pathways.

Antioxidant effects — oxidative stress is a consistent feature of neurodegeneration. Statins have antioxidant properties that reduce the reactive oxygen species production that damages neuronal mitochondria and drives the oxidative ageing process in brain tissue.

The Important Caveats

The honest assessment of this evidence requires acknowledging its limitations — which are significant.

Most evidence is observational. Randomised controlled trials of statins specifically for dementia prevention have not been conducted at sufficient scale or duration to provide definitive evidence. The cohort studies and UK Biobank analyses, however methodologically sophisticated, cannot fully exclude confounding — people who take statins for cardiovascular health may differ in unmeasured ways from those who do not.

The overall effect size is modest. A 13% risk reduction is meaningful at population level but does not represent a robust individual protection. Many lifestyle interventions — regular exercise, adequate sleep, dietary quality — produce larger individual dementia risk reductions than statins.

Statins have side effects. The most common is muscle pain — myalgia — affecting approximately 5 to 10% of users. Statins can also modestly increase type 2 diabetes risk. These considerations are relevant to any discussion of starting statins for brain health benefits alone.

The timing and type of statin may matter. Some research suggests midlife statin use is more protective than late-life initiation — consistent with the hypothesis that preventing early amyloid accumulation is more effective than intervening after significant pathology has developed. Lipophilic statins (atorvastatin, simvastatin) that cross the blood-brain barrier more readily may produce different brain effects than hydrophilic statins.

Starting statins specifically for dementia prevention is not recommended. Current UK guidance does not include dementia prevention as an indication for statin prescribing. The brain health benefits, where they exist, are an additional benefit for people already taking statins for established cardiovascular indications.

What This Means Practically

For people already taking statins for cardiovascular reasons, the emerging evidence that statins may also reduce dementia risk — particularly in those with higher genetic risk profiles — is genuinely encouraging. It provides an additional reason to continue taking them as prescribed.

Alzheimer's Research UK emphasises that by taking steps to manage or treat cholesterol levels, you are improving your brain health — and that lifestyle changes can help reduce all the risk factors for dementia beyond cholesterol alone.

For people not currently taking statins, the evidence does not support starting them for dementia prevention. The effect sizes are too modest, the evidence too preliminary, and the side effect profile too relevant to justify this as an indication in isolation.

The most impactful dementia prevention strategy remains the same as it has been — a combination of regular physical exercise, adequate and consistent sleep, a diet rich in diverse plant foods and low in ultra-processed food, social engagement, blood pressure management, and not smoking. These lifestyle interventions individually produce larger dementia risk reductions than statins, have no side effects, and address a wider range of dementia risk pathways simultaneously.

Frequently Asked Questions

Can statins prevent dementia? The evidence suggests statins may reduce dementia risk — particularly for people with higher genetic risk for Alzheimer's disease. A 2025 BHF analysis found statin users with healthy LDL were 13% less likely to develop dementia than non-users with similar LDL levels. A February 2026 UK Biobank study using causal machine learning found that people with higher polygenic risk scores for Alzheimer's benefit most. The evidence is promising but not conclusive, and statins are not currently recommended as a dementia prevention medication.

How might statins protect the brain? Through several mechanisms beyond cholesterol lowering — including anti-inflammatory effects that reduce microglial activation and neuroinflammation, improved cerebrovascular function that supports amyloid clearance, direct effects on amyloid precursor protein processing that reduce amyloid-beta production, and antioxidant effects that reduce oxidative damage to neuronal mitochondria. These pleiotropic effects — independent of cholesterol — may explain why statin users with already-healthy LDL levels show lower dementia risk.

Should I take statins to prevent dementia? Not for this reason alone — current UK guidance does not include dementia prevention as an indication for statin prescribing. The effect sizes, while meaningful at population level, are modest at individual level. People already prescribed statins for cardiovascular reasons have an additional reason to continue — but starting statins specifically for brain health is not evidence-based at this stage.

Do statins cause dementia? No — multiple large studies and systematic reviews have not found evidence that statins increase dementia risk. The Alzheimer's Research UK position is that research has not found strong evidence linking statins to an increased risk of dementia, and that some studies suggest they may have protective effects for certain groups.

Who benefits most from statins for brain health? The February 2026 UK Biobank causal machine learning study found that people with higher polygenic risk scores for Alzheimer's disease — excluding the APOE4 gene — showed the greatest dementia risk reduction from statin use. This suggests that genetic risk stratification may eventually help identify which statin users are most likely to receive brain health benefits alongside their cardiovascular benefits.

What is more effective than statins for dementia prevention? Regular aerobic and resistance exercise, consistent adequate sleep, a diverse plant-rich diet low in ultra-processed food, blood pressure management, social engagement, and not smoking all produce larger individual dementia risk reductions than statins and have no side effects. These lifestyle interventions should be the foundation of any dementia prevention strategy — statins, for those already prescribed them, represent a potential additional benefit rather than a primary intervention.

The Bottom Line

The question of whether statins can prevent dementia has moved from speculation to a genuinely evidence-supported possibility — particularly for people with higher genetic risk for Alzheimer's disease. A 13% lower dementia risk in statin users with healthy LDL, confirmed in a 2025 BHF analysis, and a February 2026 UK Biobank study identifying who benefits most, represent the most credible evidence yet that this effect is real.

What the evidence does not support is starting statins for dementia prevention alone. The effect sizes are modest, the causal evidence is still developing, and the lifestyle interventions that reduce dementia risk more substantially — exercise, sleep, diet, blood pressure management — remain the most important and most actionable tools available.

For the 5.3 million people in England already taking statins for cardiovascular health, the emerging brain health evidence is a meaningful additional benefit. The same prescription that protects the heart may also be doing something useful for the brain.

For a structured approach to the lifestyle foundations that reduce dementia risk most effectively — sleep quality, gut health, stress management, and dietary diversity — the Sleep Reset, Gut Reset, and Stress Reset from the Reset Series™ address the modifiable factors with the strongest evidence. Pair any guide with Reset Companion for tailored daily prompts.

Related reading: Can Caffeine Reduce Dementia Risk? What the Latest Harvard Research Suggests · The £4 Drug That Scientists Think Could Slow Ageing · Ultra-Processed Foods and Dementia: What the Evidence Now Shows

Popular Articles